The Belviq lawsuit is moving forward in 2026 with cancer claims piling up against Eisai Inc., the pharmaceutical company behind this recalled weight loss drug. If you took Belviq or Belviq XR and later received a cancer diagnosis, you may be entitled to significant compensation.
Thousands of former Belviq users are filing claims right now. The FDA pulled this drug from the market in 2020 after a clinical trial revealed a clear cancer signal. That was five years ago, and litigation is now reaching critical stages.
This article breaks down everything that matters. You will learn about the latest 2026 case updates, estimated settlement amounts, eligibility requirements, filing deadlines, and exactly what evidence you need to build a strong claim. One striking detail: the FDA’s own postmarket study found that Belviq users had a 5.0% cancer occurrence rate compared to 4.3% in the placebo group.
Belviq Lawsuit
The Belviq lawsuit refers to the wave of legal claims filed by individuals who developed cancer after taking the prescription weight loss drug lorcaserin, sold under the brand names Belviq and Belviq XR. These lawsuits target Eisai Inc. and Arena Pharmaceuticals for allegedly knowing about cancer risks and failing to warn patients.
The core legal theory is product liability. Plaintiffs argue that Eisai had data suggesting a cancer link before the drug even hit pharmacy shelves. Despite this, the company marketed Belviq aggressively to millions of overweight and obese adults.
| Detail | Info |
|---|---|
| Drug Name | Belviq / Belviq XR (lorcaserin) |
| Manufacturer | Eisai Inc. |
| Original Developer | Arena Pharmaceuticals |
| FDA Approval Date | June 2012 |
| FDA Market Withdrawal | February 2020 |
| Primary Legal Claim | Failure to warn about cancer risks |
Think of it like selling a car with faulty brakes. The manufacturer knew the brakes could fail but chose to sell the car anyway without telling buyers. That’s essentially what plaintiffs allege Eisai did with Belviq.
Most cases are being handled as individual product liability claims rather than one giant class action. This means each plaintiff’s compensation depends on their specific cancer diagnosis, treatment costs, and overall harm suffered.
Belviq Lawsuit Update 2026
As of 2026, the Belviq lawsuit is gaining momentum with new filings and pre-trial activity picking up pace. Courts are processing discovery materials, and attorneys on both sides are preparing for potential bellwether trials that could shape the entire litigation.
The litigation had a slower start compared to other pharmaceutical mass torts. Early cases focused on building the scientific record linking lorcaserin to various cancers. Now, that foundation is largely in place.
Key developments in 2026 include:
- Increased case filings as more patients connect their cancer diagnoses to prior Belviq use
- Expert witness depositions from oncologists and pharmacologists linking lorcaserin to cancer mechanisms
- Discovery disputes over internal Eisai documents related to pre-market cancer data
- Settlement discussions beginning in some jurisdictions
The timeline matters because statutes of limitations are running out in many states. Plaintiffs who wait too long risk losing their right to file. Attorneys handling these cases report a noticeable spike in inquiries from former users who are just now learning about the connection between Belviq and their cancer diagnosis.
No global settlement has been announced yet. But the direction of the litigation suggests that serious settlement negotiations could begin in late 2026 or early 2027, especially if bellwether trial outcomes favor plaintiffs.
Belviq Cancer Lawsuit
A Belviq cancer lawsuit is a legal claim filed by someone who was diagnosed with cancer after taking lorcaserin. These cases allege that Eisai and Arena Pharmaceuticals knew or should have known about the drug’s cancer risks and failed to provide adequate warnings.
The FDA required a postmarket clinical trial called CAMELLIA-TIMI 61. This study involved over 12,000 participants. Results showed a statistically significant increase in cancer among Belviq users.
| Study Detail | Result |
|---|---|
| Trial Name | CAMELLIA-TIMI 61 |
| Total Participants | 12,000+ |
| Cancer Rate (Belviq Group) | 7.7% at year 5 |
| Cancer Rate (Placebo Group) | 7.1% at year 5 |
| Initial Cancer Signal | 5.0% vs 4.3% |
| Cancers Identified | Colorectal, pancreatic, lung |
Plaintiffs in these cancer lawsuits typically claim three things. First, the drug was defectively designed. Second, Eisai failed to warn about known risks. Third, the company was negligent in monitoring safety data.
The cancers most commonly cited in these lawsuits are colorectal, pancreatic, and lung cancers. Some cases involve breast cancer and non-small cell lung cancer. Each type of cancer carries different treatment costs and different potential compensation levels.
Key Takeaway: The Belviq lawsuit is a growing mass tort in 2026, driven by FDA safety data showing elevated cancer rates among users, with individual claims targeting Eisai for failure to warn.
Belviq Settlement Amounts
Belviq settlement amounts have not been finalized in any global agreement as of early 2026, but legal analysts estimate individual payouts could range from $100,000 to over $1 million depending on the severity of the cancer and the strength of each case.
These estimates come from comparing Belviq cases to similar pharmaceutical cancer lawsuits. The Zantac litigation and Roundup cancer settlements provide useful reference points for what juries and settlement committees tend to award.
| Injury Tier | Estimated Settlement Range | Example Conditions |
|---|---|---|
| Tier 1 (Severe) | $500,000 to $1,500,000+ | Pancreatic cancer, late-stage cancers, death |
| Tier 2 (Significant) | $200,000 to $500,000 | Colorectal cancer, lung cancer |
| Tier 3 (Moderate) | $100,000 to $200,000 | Early-stage cancers, localized tumors |
| Tier 4 (Lower) | $25,000 to $100,000 | Benign tumors, precancerous conditions |
Several factors influence where a specific case falls on this scale:
- Type of cancer diagnosed after Belviq use
- Duration of Belviq use (longer use strengthens the claim)
- Time between Belviq use and cancer diagnosis
- Medical expenses and lost wages resulting from the cancer
- Age and overall health of the plaintiff before taking Belviq
It’s worth understanding that these are projections, not guaranteed numbers. Actual settlement amounts will depend on how trials proceed and whether Eisai decides to settle before verdicts come in. Pharmaceutical companies often settle mass tort cases once early trial results go against them.
Belviq Lawsuit Payout Per Person
The Belviq lawsuit payout per person will vary widely because each case depends on individual medical history, cancer severity, and provable damages. There is no flat per-person payout in mass tort litigation the way there sometimes is in consumer class actions.
Unlike a class action where everyone gets the same small check, mass tort cases treat each plaintiff as a separate case. Someone who developed Stage IV pancreatic cancer will receive dramatically more than someone diagnosed with an early-stage tumor that was successfully treated.
Here’s how individual payouts are typically calculated:
- Medical expenses: Surgery, chemotherapy, radiation, hospital stays, prescriptions
- Lost income: Wages lost during treatment and recovery
- Pain and suffering: Physical pain and emotional distress
- Loss of quality of life: Inability to work, care for family, or enjoy daily activities
- Wrongful death: If the patient died from cancer, families can file on their behalf
Attorneys working on contingency typically take 25% to 40% of the settlement. That percentage comes out of the final payout. No upfront fees are required in most Belviq cases.
The most comparable recent payout data comes from the Roundup cancer litigation, where individual settlements ranged from $25,000 to over $11 million. Belviq cases with strong medical evidence and clear usage history could land in similar territory.
Who Qualifies for Belviq Lawsuit
You may qualify for a Belviq lawsuit if you took Belviq or Belviq XR at any point and were later diagnosed with cancer. The connection between your Belviq use and your cancer diagnosis is the central factor in determining eligibility.
Qualifying generally requires meeting these criteria:
- You had a valid prescription for Belviq or Belviq XR
- You took the medication for any period of time
- You were diagnosed with cancer after starting Belviq
- Your cancer diagnosis came within a reasonable timeframe after use
Family members may qualify too. If a loved one died from cancer linked to Belviq use, surviving family members can often file a wrongful death claim.
| Eligibility Factor | Requirement |
|---|---|
| Prescription | Must have had a valid Belviq/Belviq XR prescription |
| Usage | Took the drug for any duration |
| Cancer Diagnosis | Diagnosed with cancer after beginning Belviq |
| Timing | Diagnosis within a medically reasonable window |
| Documentation | Medical records showing both Belviq use and cancer diagnosis |
You do not need to have used Belviq for years. Even short-term users who developed cancer are filing claims. The strength of your case increases with longer usage and a shorter gap between stopping the drug and receiving a diagnosis.
Key Takeaway: If you took Belviq and developed any form of cancer, you likely qualify to file a claim, and even family members of deceased users may have standing to sue.
Belviq Lawsuit Eligibility
Belviq lawsuit eligibility depends on three main elements: proof of Belviq use, a cancer diagnosis, and filing within your state’s statute of limitations. All three must be present for a viable claim.
The eligibility question trips people up because they assume they need perfect records. That’s not always the case. Pharmacy records, insurance claims, and even doctor’s notes can serve as proof that you took Belviq.
Here’s a breakdown of what strengthens or weakens eligibility:
Factors that strengthen your case:
- Long duration of Belviq use (months or years)
- Cancer diagnosis within 1 to 5 years of use
- No prior history of the same cancer type
- No other major cancer risk factors (heavy smoking, family history)
Factors that may complicate your case:
- Very brief Belviq use (a few days)
- Cancer diagnosis many years before starting Belviq
- Significant other risk factors for the same cancer
- Missing medical records for either Belviq use or cancer diagnosis
Even with complicating factors, don’t rule yourself out. Attorneys evaluate each case individually. A plaintiff with some risk factors but strong Belviq usage history can still file a strong claim. The key is getting your medical records reviewed by a legal team experienced in pharmaceutical litigation.
Belviq Class Action Lawsuit
The Belviq class action lawsuit label is commonly used online, but most Belviq cases are actually individual lawsuits consolidated through multidistrict litigation, not a traditional class action. The distinction matters because it affects how much money each person can receive.
In a class action, one lawsuit represents thousands of people, and everyone gets the same payout. In mass tort or MDL cases, each person files their own lawsuit. Their compensation is based on their own injuries, medical costs, and damages.
| Feature | Class Action | Mass Tort / MDL |
|---|---|---|
| Filing | One lawsuit for all plaintiffs | Each plaintiff files individually |
| Payout | Same amount per person | Varies by individual case |
| Control | Lead plaintiff makes decisions | Each plaintiff has a say |
| Typical Award | Lower per person | Higher per person |
| Best For | Small, uniform damages | Serious, varied injuries |
Belviq litigation fits the mass tort model because each plaintiff has a different cancer type, different treatment costs, and different levels of harm. A one-size-fits-all payout would be unfair to someone with Stage IV cancer compared to someone with a small benign tumor.
Some consumer protection class actions related to Belviq’s marketing may exist separately. These typically involve refund claims for people who bought the drug but did not develop cancer. The payouts in those cases are much smaller, usually a few hundred dollars at most.
How to File a Belviq Lawsuit
To file a Belviq lawsuit, you need to contact a law firm experienced in pharmaceutical mass torts, provide your medical records, and have your case evaluated for free. Most firms handle Belviq cases on a contingency basis, meaning you pay nothing upfront.
The filing process follows a predictable path:
Step 1: Free Case Review
You share basic information about your Belviq use and cancer diagnosis. An attorney reviews whether you have a viable claim.
Step 2: Gather Medical Records
Your legal team collects records showing your Belviq prescription history and cancer diagnosis. Pharmacy records, hospital files, and insurance statements all help.
Step 3: File the Complaint
Your attorney drafts and files the legal complaint in the appropriate court. This document lays out your claims against Eisai.
Step 4: Discovery and Litigation
Both sides exchange evidence. Depositions are taken. Expert witnesses may be retained.
Step 5: Settlement or Trial
Most pharmaceutical cases settle before trial. If not, your case goes before a jury.
The entire process can take 12 to 36 months from initial filing to resolution. Some cases move faster, especially if they fall into an existing MDL track.
You do not need to appear in court in most cases. Your attorney handles nearly everything. Many consultations and updates happen by phone or email.
Key Takeaway: Filing a Belviq lawsuit costs nothing upfront, and the process starts with a simple case review where you share your medical history and Belviq usage details.
Belviq Lawsuit Deadline 2026
The Belviq lawsuit deadline depends on your state’s statute of limitations for product liability and personal injury claims, and many plaintiffs face expiration dates in 2026 or 2027. Waiting too long could permanently eliminate your right to file.
Statutes of limitations for pharmaceutical injury cases typically range from 2 to 6 years depending on the state. The clock usually starts ticking from the date you were diagnosed with cancer, not from the date you took Belviq.
| State Example | Statute of Limitations | Deadline if Diagnosed in 2022 |
|---|---|---|
| California | 2 years | 2024 (may have passed) |
| Texas | 2 years | 2024 (may have passed) |
| New York | 3 years | 2025 |
| Florida | 4 years | 2026 |
| Illinois | 2 years | 2024 (may have passed) |
| Pennsylvania | 2 years | 2024 (may have passed) |
Some states have a “discovery rule.” This means the clock starts when you discovered (or reasonably should have discovered) that Belviq caused your cancer. This rule can extend deadlines for people who only recently learned about the Belviq cancer link.
If you were diagnosed with cancer in 2023 or 2024 and live in a state with a 2 to 3 year statute, your window is closing fast. Do not assume you have unlimited time. Every month of delay brings you closer to losing your claim forever.
The safest move is to get a free case evaluation now. An attorney can tell you exactly where you stand in your state.
Belviq Recall Lawsuit
The Belviq recall lawsuit stems from the FDA’s February 2020 request that Eisai voluntarily withdraw Belviq and Belviq XR from the U.S. market. The recall happened after clinical trial data confirmed an increased cancer risk among users.
This was not a typical recall. The FDA did not force Eisai to pull the drug. Instead, the agency issued a formal request, and Eisai complied. That distinction matters legally because plaintiffs argue Eisai should have withdrawn the drug even earlier.
The recall timeline tells a damning story:
- 2012: FDA approves Belviq but requires a postmarket safety study
- 2016: CAMELLIA-TIMI 61 trial begins enrolling patients
- 2018: Early data shows a cancer imbalance in the Belviq group
- January 2020: FDA receives final study results confirming cancer risk
- February 13, 2020: FDA requests market withdrawal
- February 2020: Eisai voluntarily withdraws Belviq and Belviq XR
Plaintiffs in recall-based lawsuits point to the gap between 2018 (when early data showed problems) and February 2020 (when the drug was pulled). During those two years, doctors continued prescribing Belviq to patients who had no idea about the emerging cancer risk.
The recall itself serves as powerful evidence in these lawsuits. When the FDA asks a drug maker to pull a product off the market, it sends a clear signal that the drug is not safe.
Belviq FDA Recall
The Belviq FDA recall was announced on February 13, 2020, when the agency asked Eisai to remove lorcaserin from the market based on a completed five-year clinical trial showing higher cancer rates in patients who took the drug.
The FDA’s safety communication was unusually direct. The agency stated that the risks of Belviq outweighed its benefits. For a weight loss drug, that’s a devastating conclusion because it means the cancer risk was not worth whatever pounds patients lost.
| FDA Action Detail | Information |
|---|---|
| Action Date | February 13, 2020 |
| Action Type | Voluntary market withdrawal request |
| Basis | CAMELLIA-TIMI 61 clinical trial results |
| Cancer Rate Difference | 7.7% (Belviq) vs. 7.1% (placebo) at 5 years |
| FDA Recommendation | Patients should stop taking Belviq |
| Drug Status | No longer available in the U.S. |
The FDA also instructed patients to stop taking Belviq and talk to their doctors about alternative weight management options. Pharmacies were told to stop dispensing the medication.
What makes this recall significant for lawsuits is the paper trail. The FDA required this safety study as a condition of approval back in 2012. That means the agency had concerns about cancer risk from the very beginning. Plaintiffs argue that Eisai knew about these concerns and still pushed the drug to market.
Key Takeaway: The FDA’s 2020 market withdrawal request provides strong evidence for plaintiffs because it confirms the agency’s own conclusion that Belviq’s cancer risks outweigh its weight loss benefits.
Belviq Side Effects Cancer
Belviq side effects include an increased risk of cancer, which was the primary reason the FDA requested the drug’s removal from the market. Cancer was not listed as a side effect when the drug was originally approved in 2012.
The drug was initially marketed with a side effect profile that included headaches, dizziness, nausea, and fatigue. Cancer was not part of the conversation. That changed dramatically when clinical trial data emerged years later.
Common Belviq side effects reported during its time on the market:
- Headache
- Dizziness
- Fatigue
- Nausea
- Constipation
- Dry mouth
- Low blood sugar (in diabetic patients)
- Back pain
The cancer side effect is what sets Belviq apart from other weight loss drugs. While many medications carry minor side effects, an elevated cancer risk crosses into territory that most patients would consider unacceptable, especially for a drug that helps you lose a few extra pounds.
The CAMELLIA-TIMI 61 trial found that the cancer signal was not limited to one type. Multiple different cancers appeared at higher rates in the Belviq group. This broad cancer signal is what alarmed the FDA and led to the withdrawal request.
Patients who experienced any cancer diagnosis after taking Belviq should consider whether the drug may have played a role. The timeline between Belviq use and cancer onset is a key factor in both medical assessment and legal claims.
Belviq Lorcaserin Cancer Risk
The Belviq lorcaserin cancer risk is real and was confirmed by the largest clinical trial ever conducted on the drug. Lorcaserin, the active ingredient in Belviq, is a serotonin 2C receptor agonist originally developed by Arena Pharmaceuticals to suppress appetite.
The cancer risk was not theoretical. It was measured in a controlled study with thousands of participants. The data showed a consistent pattern: people who took lorcaserin developed cancer at higher rates than people who took a sugar pill.
The mechanism behind lorcaserin’s cancer risk is still being studied. Some researchers believe the drug’s interaction with serotonin receptors may promote tumor growth. Others suggest it could interfere with the body’s natural cancer-fighting mechanisms.
| Risk Factor | Detail |
|---|---|
| Active Ingredient | Lorcaserin hydrochloride |
| Drug Class | Serotonin 2C receptor agonist |
| Cancer Signal Source | CAMELLIA-TIMI 61 trial |
| Risk Level | Statistically significant increase |
| Cancers Observed | Multiple types across body systems |
| Risk Period | During and after use |
The cancer risk didn’t just appear in long-term users. Even patients who took Belviq for relatively short periods showed up in the elevated cancer statistics. This suggests that lorcaserin may trigger cellular changes relatively quickly.
For lawsuit purposes, the established cancer risk is the foundation of every claim. Without this data, there would be no Belviq litigation. With it, plaintiffs have strong scientific backing for their allegations against Eisai.
What Cancers Are Linked to Belviq
The cancers linked to Belviq include colorectal, pancreatic, and lung cancers, which were the most commonly reported types in the clinical trial data. Several other cancer types have appeared in individual case reports and are being investigated.
Here is a breakdown of the cancers associated with Belviq use:
| Cancer Type | Level of Evidence | Notes |
|---|---|---|
| Colorectal Cancer | Strong (trial data) | Most frequently cited in lawsuits |
| Pancreatic Cancer | Strong (trial data) | Carries highest fatality rate |
| Lung Cancer | Strong (trial data) | Includes non-small cell lung cancer |
| Breast Cancer | Moderate (case reports) | Reported in some female plaintiffs |
| Brain Cancer | Emerging (case reports) | Less common but documented |
| Blood Cancers | Emerging (case reports) | Includes leukemia and lymphoma |
Colorectal cancer appears most often in Belviq lawsuits. This type of cancer was flagged early in the clinical trial and consistently showed higher rates in the drug group compared to placebo.
Pancreatic cancer, while less common overall, tends to generate the largest potential payouts. That’s because pancreatic cancer has one of the lowest survival rates of any cancer type. Patients diagnosed with this cancer often face aggressive treatment and poor long-term outcomes.
The variety of cancer types is significant. When a drug causes just one type of cancer, defense attorneys can argue it’s coincidence. When multiple cancer types appear at elevated rates, the argument for causation becomes much stronger.
Key Takeaway: Belviq has been linked to at least six types of cancer, with colorectal, pancreatic, and lung cancers having the strongest evidentiary support from the FDA-required clinical trial.
Belviq MDL Update
The Belviq MDL (multidistrict litigation) is the federal court process that consolidates Belviq cancer cases from across the country into a single court for pre-trial proceedings. As of 2026, the MDL process is advancing through discovery and moving toward potential bellwether trial selections.
MDL consolidation helps both sides. Plaintiffs benefit because legal resources are shared. The court benefits because thousands of similar cases don’t clog up individual courtrooms across America.
Key MDL developments:
- Discovery phase is underway with document production from Eisai
- Internal company communications about cancer data are being reviewed
- Expert witness reports on lorcaserin’s cancer mechanisms are being prepared
- Bellwether trial selections may begin in late 2026 or early 2027
- No global settlement has been reached or formally proposed
Bellwether trials are test cases. The court picks a handful of representative cases to go to trial first. The outcomes of these trials often determine whether the defendant decides to settle the remaining cases or keep fighting.
In similar pharmaceutical MDLs, settlement talks typically heat up after one or two bellwether verdicts. If juries side with plaintiffs and award large damages, the drug company faces enormous financial pressure to settle. If defendants win early trials, settlement values drop.
The MDL process can feel slow. But it is methodical for a reason. Every document obtained during discovery, every expert opinion submitted, and every procedural ruling builds the framework for what could become a multi-billion dollar resolution.
Belviq Lawsuit Evidence Needed
The evidence needed for a Belviq lawsuit includes proof that you took the medication, documentation of your cancer diagnosis, and medical records connecting the timeline between drug use and disease onset. The stronger your evidence, the stronger your claim.
Here is what legal teams typically need to build your case:
Essential evidence:
- Prescription records from your doctor or pharmacy
- Insurance claims showing Belviq or lorcaserin purchases
- Medical records documenting your cancer diagnosis
- Pathology reports confirming cancer type and stage
- Treatment records (surgery, chemotherapy, radiation)
Helpful but not always required:
- Doctor’s notes mentioning Belviq prescriptions
- Pill bottles or medication packaging
- Personal journals or calendars noting when you took the drug
- Testimony from family members about your medication use
| Evidence Type | Where to Find It | Importance Level |
|---|---|---|
| Prescription Records | Pharmacy, doctor’s office | Critical |
| Insurance Claims | Insurance company records | Critical |
| Cancer Diagnosis Records | Oncologist, hospital | Critical |
| Pathology Reports | Hospital lab department | Very Important |
| Treatment Records | Oncologist, surgeon | Very Important |
| Personal Documentation | Your own files | Helpful |
Don’t panic if you’ve lost some records. Attorneys and their staff are experienced at tracking down medical and pharmacy records. Pharmacies keep prescription records for years. Insurance companies maintain claims databases. Hospitals store medical files electronically.
The key is to start the process. Even if your records are incomplete, a legal team can often fill in the gaps through formal discovery requests and subpoenas.
Key Takeaway: You don’t need a perfect paper trail to file a Belviq lawsuit. Attorneys can obtain pharmacy records, insurance claims, and medical files on your behalf if you can provide basic details about when and where you were treated.
Frequently Asked Questions
How much money can I get from a Belviq lawsuit in 2026?
Individual Belviq lawsuit payouts are projected to range from $100,000 to over $1 million depending on cancer type and severity.
Pancreatic and late-stage cancers typically command the highest settlements.
No global settlement has been finalized yet, so exact amounts remain estimates based on comparable pharmaceutical cases.
Is there a deadline to file a Belviq lawsuit?
Yes, every state has a statute of limitations that sets a filing deadline, typically 2 to 6 years from your cancer diagnosis date.
Many plaintiffs diagnosed in 2022 or 2023 face deadlines that expire in 2025 or 2026.
Contact a legal team immediately to confirm your state’s specific deadline.
What types of cancer qualify for a Belviq lawsuit?
Colorectal, pancreatic, and lung cancers have the strongest connection to Belviq based on clinical trial data.
Breast cancer, brain cancer, and blood cancers have been reported in individual cases.
Any cancer diagnosed after Belviq use should be evaluated by an attorney for potential eligibility.
Is the Belviq lawsuit a class action or individual case?
Most Belviq lawsuits are individual claims handled through multidistrict litigation, not a traditional class action.
This means each person’s payout is based on their own damages rather than a flat per-person amount.
The MDL process consolidates cases for efficiency while preserving individual claim values.
What proof do I need to file a Belviq cancer claim?
You need prescription records showing Belviq use and medical records confirming a cancer diagnosis.
Pharmacy records, insurance claims, and pathology reports are the most important pieces of evidence.
Attorneys can help obtain these records through formal legal channels if you don’t have them readily available.
Take Action Before Time Runs Out
The Belviq lawsuit is hitting a critical stage in 2026. Deadlines are approaching in multiple states. Settlement discussions could begin soon as bellwether trials move closer.
If you or a family member took Belviq and later developed cancer, now is the time to get your case reviewed. There’s no cost for an evaluation, and waiting only puts your claim at risk.
Gather whatever records you have. Reach out to a legal team with pharmaceutical litigation experience. Don’t let a filing deadline silently close the door on compensation you deserve.
